Download
12311_2024_Article_1700.pdf 1,70MB
WeightNameValue
1000 Titel
  • Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia
1000 Autor/in
  1. Potashman, Michele |
  2. Rudell, Katja |
  3. Pavisic, Ivanna |
  4. Suminski, Naomi |
  5. Doma, Rinchen |
  6. Heinrich, Maggie |
  7. Abetz-Webb, Linda |
  8. Beiner, Melissa Wolfe |
  9. Kuo, Sheng-Han |
  10. Rosenthal, Liana S. |
  11. Zesiwicz, Theresa |
  12. Fife, Terry D. |
  13. van de Warrenburg, Bart P. |
  14. Ristori, Giovanni |
  15. Synofzik, Matthis |
  16. Perlman, Susan |
  17. Schmahmann, Jeremy D. |
  18. L’Italien, Gilbert |
1000 Verlag Springer US
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-05-07
1000 Erschienen in
1000 Quellenangabe
  • 23(5):2012-2027
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12311-024-01700-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489265/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>The functional Scale for the Assessment and Rating of Ataxia (f-SARA) assesses Gait, Stance, Sitting, and Speech. It was developed as a potentially clinically meaningful measure of spinocerebellar ataxia (SCA) progression for clinical trial use. Here, we evaluated content validity of the f-SARA. Qualitative interviews were conducted among individuals with SCA1 (<jats:italic>n</jats:italic> = 1) and SCA3 (<jats:italic>n</jats:italic> = 6) and healthcare professionals (HCPs) with SCA expertise (USA, <jats:italic>n</jats:italic> = 5; Europe, <jats:italic>n</jats:italic> = 3). Interviews evaluated symptoms and signs of SCA and relevance of f-SARA concepts for SCA. HCP cognitive debriefing was conducted. Interviews were recorded, transcribed, coded, and analyzed by ATLAS.TI software. Individuals with SCA1 and 3 reported 85 symptoms, signs, and impacts of SCA. All indicated difficulties with walking, stance, balance, speech, fatigue, emotions, and work. All individuals with SCA1 and 3 considered Gait, Stance, and Speech relevant f-SARA concepts; 3 considered Sitting relevant (42.9%). All HCPs considered Gait and Speech relevant; 5 (62.5%) indicated Stance was relevant. Sitting was considered a late-stage disease indicator. Most HCPs suggested inclusion of appendicular items would enhance clinical relevance. Cognitive debriefing supported clarity and comprehension of f-SARA. Maintaining current abilities on f-SARA items for 1 year was considered meaningful for most individuals with SCA1 and 3. All HCPs considered meaningful changes as stability in f-SARA score over 1–2 years, 1–2-point change in total f-SARA score, and deviation from natural history. These results support content validity of f-SARA for assessing SCA disease progression in clinical trials.</jats:p>
1000 Sacherschließung
lokal Female [MeSH]
lokal Disease Progression [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Severity of Illness Index [MeSH]
lokal Spinocerebellar Ataxias/physiopathology [MeSH]
lokal Middle Aged [MeSH]
lokal Spinocerebellar ataxia
lokal Cognitive debriefing
lokal Concept elicitation
lokal Male [MeSH]
lokal Spinocerebellar Ataxias/psychology [MeSH]
lokal Reproducibility of Results [MeSH]
lokal Spinocerebellar Ataxias/diagnosis [MeSH]
lokal Research
lokal Gait/physiology [MeSH]
lokal f-SARA
lokal Clinical outcome assessment
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UG90YXNobWFuLCBNaWNoZWxl|https://frl.publisso.de/adhoc/uri/UnVkZWxsLCBLYXRqYQ==|https://frl.publisso.de/adhoc/uri/UGF2aXNpYywgSXZhbm5h|https://frl.publisso.de/adhoc/uri/U3VtaW5za2ksIE5hb21p|https://frl.publisso.de/adhoc/uri/RG9tYSwgUmluY2hlbg==|https://frl.publisso.de/adhoc/uri/SGVpbnJpY2gsIE1hZ2dpZQ==|https://frl.publisso.de/adhoc/uri/QWJldHotV2ViYiwgTGluZGE=|https://frl.publisso.de/adhoc/uri/QmVpbmVyLCBNZWxpc3NhIFdvbGZl|https://frl.publisso.de/adhoc/uri/S3VvLCBTaGVuZy1IYW4=|https://frl.publisso.de/adhoc/uri/Um9zZW50aGFsLCBMaWFuYSBTLg==|https://frl.publisso.de/adhoc/uri/WmVzaXdpY3osIFRoZXJlc2E=|https://frl.publisso.de/adhoc/uri/RmlmZSwgVGVycnkgRC4=|https://frl.publisso.de/adhoc/uri/dmFuIGRlIFdhcnJlbmJ1cmcsIEJhcnQgUC4=|https://frl.publisso.de/adhoc/uri/UmlzdG9yaSwgR2lvdmFubmk=|https://frl.publisso.de/adhoc/uri/U3lub2Z6aWssIE1hdHRoaXM=|https://frl.publisso.de/adhoc/uri/UGVybG1hbiwgU3VzYW4=|https://frl.publisso.de/adhoc/uri/U2NobWFobWFubiwgSmVyZW15IEQu|https://frl.publisso.de/adhoc/uri/TOKAmUl0YWxpZW4sIEdpbGJlcnQ=
1000 Hinweis
  • DeepGreen-ID: 6f883d1fc93c428a934fd1e8176a1d1b ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. This study was supported by Biohaven Pharmaceuticals, Inc. |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer This study was supported by Biohaven Pharmaceuticals, Inc. |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6519575.rdf
1000 Erstellt am 2025-07-05T18:49:57.763+0200
1000 Erstellt von 322
1000 beschreibt frl:6519575
1000 Zuletzt bearbeitet 2025-08-11T11:51:28.053+0200
1000 Objekt bearb. Mon Aug 11 11:51:28 CEST 2025
1000 Vgl. frl:6519575
1000 Oai Id
  1. oai:frl.publisso.de:frl:6519575 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source